Giulia Perini1,2, Elena Rodriguez-Vieitez1, Ahmadul Kadir1,3, Arianna Sala1, Irina Savitcheva4, Agneta Nordberg5,6. 1. Department of Neurobiology, Care Sciences and Society, Division of Clinical Geriatrics, Center for Alzheimer Research, Karolinska Institutet, 141 52, Stockholm, Sweden. 2. Center for Cognitive and Behavioral Disorders, IRCCS Mondino Foundation and Dept of Brain and Behavior, University of Pavia, 27100, Pavia, Italy. 3. Theme Aging, The Aging Brain Unit, Karolinska University Hospital, 141 86, Stockholm, Sweden. 4. Medical Radiation Physics and Nuclear Medicine Imaging, Section for Nuclear Medicine, Karolinska University Hospital, Stockholm, Sweden. 5. Department of Neurobiology, Care Sciences and Society, Division of Clinical Geriatrics, Center for Alzheimer Research, Karolinska Institutet, 141 52, Stockholm, Sweden. Agneta.K.Nordberg@ki.se. 6. Theme Aging, The Aging Brain Unit, Karolinska University Hospital, 141 86, Stockholm, Sweden. Agneta.K.Nordberg@ki.se.
Abstract
PURPOSE: To assess the clinical impact and incremental diagnostic value of 18F-fluorodeoxyglucose (FDG-PET) among memory clinic patients with uncertain diagnosis. METHODS: The study population consisted of 277 patients who, despite extensive baseline cognitive assessment, MRI, and CSF analyses, had an uncertain diagnosis of mild cognitive impairment (MCI) (n = 177) or dementia (n = 100). After baseline diagnosis, each patient underwent an FDG-PET, followed by a post-FDG-PET diagnosis formulation. We evaluated (i) the change in diagnosis (baseline vs. post-FDG-PET), (ii) the change in diagnostic accuracy when comparing each baseline and post-FDG-PET diagnosis to a long-term follow-up (3.6 ± 1.8 years) diagnosis used as reference, and (iii) comparative FDG-PET performance testing in MCI and dementia conditions. RESULTS: FDG-PET led to a change in diagnosis in 86 of 277 (31%) patients, in particular in 57 of 177 (32%) MCI and in 29 of 100 (29%) dementia patients. Diagnostic change was greater than two-fold in the sub-sample of cases with dementia "of unclear etiology" (change in diagnosis in 20 of 32 (63%) patients). In the dementia group, after results of FDG-PET, diagnostic accuracy improved from 77 to 90% in Alzheimer's disease (AD) and from 85 to 94% in frontotemporal lobar degeneration (FTLD) patients (p < 0.01). FDG-PET performed better in dementia than in MCI (positive likelihood ratios >5 and < 5, respectively). CONCLUSION: Within a selected clinical population, FDG-PET has a significant clinical impact, both in early and differential diagnosis of uncertain dementia. FDG-PET provides significant incremental value to detect AD and FTLD over a clinical diagnosis of uncertain dementia.
PURPOSE: To assess the clinical impact and incremental diagnostic value of 18F-fluorodeoxyglucose (FDG-PET) among memory clinic patients with uncertain diagnosis. METHODS: The study population consisted of 277 patients who, despite extensive baseline cognitive assessment, MRI, and CSF analyses, had an uncertain diagnosis of mild cognitive impairment (MCI) (n = 177) or dementia (n = 100). After baseline diagnosis, each patient underwent an FDG-PET, followed by a post-FDG-PET diagnosis formulation. We evaluated (i) the change in diagnosis (baseline vs. post-FDG-PET), (ii) the change in diagnostic accuracy when comparing each baseline and post-FDG-PET diagnosis to a long-term follow-up (3.6 ± 1.8 years) diagnosis used as reference, and (iii) comparative FDG-PET performance testing in MCI and dementia conditions. RESULTS:FDG-PET led to a change in diagnosis in 86 of 277 (31%) patients, in particular in 57 of 177 (32%) MCI and in 29 of 100 (29%) dementiapatients. Diagnostic change was greater than two-fold in the sub-sample of cases with dementia "of unclear etiology" (change in diagnosis in 20 of 32 (63%) patients). In the dementia group, after results of FDG-PET, diagnostic accuracy improved from 77 to 90% in Alzheimer's disease (AD) and from 85 to 94% in frontotemporal lobar degeneration (FTLD) patients (p < 0.01). FDG-PET performed better in dementia than in MCI (positive likelihood ratios >5 and < 5, respectively). CONCLUSION: Within a selected clinical population, FDG-PET has a significant clinical impact, both in early and differential diagnosis of uncertain dementia. FDG-PET provides significant incremental value to detect AD and FTLD over a clinical diagnosis of uncertain dementia.
Authors: Silvia Morbelli; Andrea Brugnolo; Irene Bossert; Ambra Buschiazzo; Giovanni B Frisoni; Samantha Galluzzi; Bart N M van Berckel; Rik Ossenkoppele; Robert Perneczky; Alexander Drzezga; Mira Didic; Eric Guedj; Gianmario Sambuceti; Gianluca Bottoni; Dario Arnaldi; Agnese Picco; Fabrizio De Carli; Marco Pagani; Flavio Nobili Journal: J Alzheimers Dis Date: 2015 Impact factor: 4.472
Authors: Guy M McKhann; David S Knopman; Howard Chertkow; Bradley T Hyman; Clifford R Jack; Claudia H Kawas; William E Klunk; Walter J Koroshetz; Jennifer J Manly; Richard Mayeux; Richard C Mohs; John C Morris; Martin N Rossor; Philip Scheltens; Maria C Carrillo; Bill Thies; Sandra Weintraub; Creighton H Phelps Journal: Alzheimers Dement Date: 2011-04-21 Impact factor: 21.566
Authors: Susan M Landau; Danielle Harvey; Cindee M Madison; Robert A Koeppe; Eric M Reiman; Norman L Foster; Michael W Weiner; William J Jagust Journal: Neurobiol Aging Date: 2009-08-05 Impact factor: 4.673
Authors: Rik Ossenkoppele; Niels D Prins; Yolande A L Pijnenburg; Afina W Lemstra; Wiesje M van der Flier; Sofie F Adriaanse; Albert D Windhorst; Ron L H Handels; Claire A G Wolfs; Pauline Aalten; Frans R J Verhey; Marcel M Verbeek; Mark A van Buchem; Otto S Hoekstra; Adriaan A Lammertsma; Philip Scheltens; Bart N M van Berckel Journal: Alzheimers Dement Date: 2012-11-16 Impact factor: 21.566
Authors: Melissa J Armstrong; Irene Litvan; Anthony E Lang; Thomas H Bak; Kailash P Bhatia; Barbara Borroni; Adam L Boxer; Dennis W Dickson; Murray Grossman; Mark Hallett; Keith A Josephs; Andrew Kertesz; Suzee E Lee; Bruce L Miller; Stephen G Reich; David E Riley; Eduardo Tolosa; Alexander I Tröster; Marie Vidailhet; William J Weiner Journal: Neurology Date: 2013-01-29 Impact factor: 9.910
Authors: L Mosconi; D Perani; S Sorbi; K Herholz; B Nacmias; V Holthoff; E Salmon; J-C Baron; M T R De Cristofaro; A Padovani; B Borroni; M Franceschi; L Bracco; A Pupi Journal: Neurology Date: 2004-12-28 Impact factor: 9.910